OncoPharm

John Bossaer
  • 0.0（0則評分）
  • 科學
  • 每週更新

OncoPharm is a podcast dedicated to all things oncology pharmacy. Most episodes cover updates and recent publications concerning the use of medications in caring for patients with cancer. Periodically, episodes drop devoted to Landmark Clinical Trials in oncology and Fundamentals of Oncology Pharmacy.

  1. Perioperative Enortumab vedotin + Pembrolizumab

    3 天前

    Perioperative Enortumab vedotin + Pembrolizumab

    The EV-303 trial that led to the FDA approval of perioperative enfortumab vedotin + pembrolizumab in cisplatin-ineligible bladder cancer patients in now published in NEJM. We discuss the results and ponder potential future changes to treating bladder cancer in the future. Urinary diversion surgeries: https://jamanetwork.com/journals/jamaoncology/fullarticle/2842595

    17 分鐘
  2. Axi-Cel and 5-FU Label Changes

    2月12日

    Axi-Cel and 5-FU Label Changes

    We have FDA changes to the labels of Axi-Cel (to allow for its use in primary CNS lymphoma) and 5-flourouracil (pre-treatment DPYD testing). Also, pembrolizumab nets another approval, this time in conjunction with paclitaxel for platinum-resistant ovarian cancer (limited to PD-L1 CPS of 1% of greater)

    13 分鐘

  3. 2月5日

    Core Communication Skills in Chemotherapy Education

    A brief discussion of the Core Communication Skills* and how to incorporate them into a chemotherapy education session. *Rapport Building *Agenda Setting *Information Management *Active Listening *Addressing Feelings *Common Ground

    15 分鐘
  4. PATINA

    1月29日

    PATINA

    Reviewing the hot-off-the press publication of PATINA, palbociclib in HER-2 amplified breast cancer along with endocrine therapy and HER-2 targeted antibodies.

    16 分鐘
  5. Sacituzumab govitecan + pembrolizumab and ASCO GI '26

    1月22日

    Sacituzumab govitecan + pembrolizumab and ASCO GI '26

    We review the recent ASCENT-04/Keynote-D19 publication of sacituzuab govitecan + pembrolizumab for PD-L1 CPS of 10% and above TNBC compared to chemo + pembrolizumab alone. Also, a quick recap of ASCO GI earlier this month with mentions of zanidatamab and zolbetuximab. Finally, a check-in on The Pitt.

    18 分鐘
  6. Oncology Drug Use Evolution

    1月15日

    Oncology Drug Use Evolution

    This episode is the 2nd chapter in a broader presentation about putting together the puzzle pieces of oncology drug use. This chapter discusses examples of how oncology drug use changes over time. Video & slides available at: https://youtu.be/Kxs0Xg9Ug_c?si=yOwEU1X-7mCPoQl5

    11 分鐘
  7. 2025 New Drug Review

    1月8日

    2025 New Drug Review

    A Holiday tradition like few other. Are we keeping, regifting, or returning new oncology drugs approved in 2025?

    15 分鐘
  8. Bladder Cancer Updates & SC Amivantamab

    2025/12/18

    Bladder Cancer Updates & SC Amivantamab

    Are we nearing the end of the Platinum Era in bladder cancer? A press release suggests enfortumab vedotin + pembrolizumab in a perioperative approach is better than the current standard of care: neoadjuvant cisplatin-based chemo followed by surgery. We eagerly await seeing this data. Also, a subcutaneous amivantamab/hyaluronidase formulation is approved, which offers a much lower risk of infusion reactions - but some chances for dosing errors based on weights and available dosage forms.

    13 分鐘
顯示全部 (415)

簡介

OncoPharm is a podcast dedicated to all things oncology pharmacy. Most episodes cover updates and recent publications concerning the use of medications in caring for patients with cancer. Periodically, episodes drop devoted to Landmark Clinical Trials in oncology and Fundamentals of Oncology Pharmacy.

資訊

  • 創作者
    John Bossaer
  • 活躍年代
    2017年 - 2026年
  • 集數
    415
  • 年齡分級
    兒少適宜
  • 版權
    © All rights reserved
  • 節目網站
    OncoPharm

你可能也會喜歡